Please find here an overview of guidance documents currently under development, either proposed or endorsed by ESCMID or its study groups.

The status of each project is defined based on the steps of the GIN-McMaster Guideline Development Checklist.

For more information please contact us at guidancedocuments[at]escmid.org.

 

  • the Update of the 2014 ESCMID guidelines for the management of the infection prevention & control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients(ESCMID)

Chair: Evelina Tacconelli

Approval date: December 2020.

Status (date): Priority settings (March 2021).

 

  • Diagnosis and treatment of brain abscess (ESCMID)

Chair: Jacob Bodilsen

Approval date: December 2020.

Status (date): Identifying target audience and topic selection (April 2021).

 

  • Antibiotic surgical prophylaxis regimens among patients colonised by MDR-GNB and MDR-GPB (ESCMID)

Chair: Nico T. Mutters

Approval date: December 2019.

Status (date): Deciding what evidence to include and searching for evidence (October 2020).

 

  • Antimicrobial stewardship in the emergency department (ESCMID)

Chair: Jeroen Schouten

Approval date: December 2019.

Status (date): (PICO) Question Generation (December 2020).

 

  • Influenza management and treatment (ESCMID)

Chair: Barbara Rath

Approval date: December 2019.

Status (date): (PICO) Question Generation (February 2021).

  • Management of uncomplicated urinary tract infections (IDSA/ESCMID)
  •  

ESCMID representative: Angela Huttner.

Approval date: April 2019.

Status (date): Deciding what evidence to include and searching for evidence (May 2020).

 

  • Microbiological diagnosis of bloodstream infections (ESCMID/ESA)

Chair: Brigitte Lamy

Approval date: November 2018.

Status (date): (PICO) Question Revision (August 2021).

 

  • Update on the treatment of C. difficile infection (ESCMID/ESGCD)

ESCMID representative: Joffrey Prehn.

Approval date: July 2018.

Status (date): Public Consultation Phase completed (July 2021).

 

  • Diagnosis and management of infective encephalitis (ESCMID/EAN)

ESCMID representative: Thomas Whitfield.

Approval date: April 2018.

Status (date): (PICO) Question Generation (December 2020).

 

  • Update of the 2016 Surviving Sepsis Campaign international guidelines for the management of severe sepsis and septic shock (SCCM/ESICM/ESCMID endorsement)

ESCMID representative: Joos Wiersinga.

Approval date: April 2018.

Status (date): Near Publication (July 2021).

 

  • Rituals and behaviors in the operating room (ESCMID/HIS)

ESCMID representative: Gemma Marsden.

Approval date: March 2018.

Status (date): Judging quality, strength or certainty of a body of evidence (February 2021).

 

  • Management of severe community-acquired pneumonia (ERS/ALAT/ESCIM/ESCMID endorsement)

ESCMID representative: Matteo Bassetti.

Approval date: October 2017.

Status (date): Deciding what evidence to include and searching for evidence (November 2019).

 

  • Management of Staphylococcus aureus bacteremia (IDSA/ESCMID)

ESCMID representative: Winfried Kern & François Vandenesch.

Approval date: January 2017.

Status (date): Deciding what evidence to include and searching for evidence (January 2020).

 

  • Guideline on treatment of invasive infections by Multidrug-resistant Gram-negative bacteria (ESCMID)

Chair: Jesús Rodríguez-Baño

Approval date: January 2017.

Status (date): Reporting and peer review (August 2021).